These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8898251)

  • 61. Botulinum Toxin Injections Into the Lateral Cricoarytenoid Muscles for Vocal Process Granuloma.
    Pham Q; Campbell R; Mattioni J; Sataloff R
    J Voice; 2018 May; 32(3):363-366. PubMed ID: 28778373
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment of adductor laryngeal breathing dystonia with botulinum toxin type A.
    Grillone GA; Blitzer A; Brin MF; Annino DJ; Saint-Hilaire MH
    Laryngoscope; 1994 Jan; 104(1 Pt 1):30-2. PubMed ID: 8295454
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Histology of nerves and muscles in adductor spasmodic dysphonia.
    Chhetri DK; Blumin JH; Vinters HV; Berke GS
    Ann Otol Rhinol Laryngol; 2003 Apr; 112(4):334-41. PubMed ID: 12731628
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of muscle activation patterns in adductor and abductor spasmodic dysphonia.
    Van Pelt F; Ludlow CL; Smith PJ
    Ann Otol Rhinol Laryngol; 1994 Mar; 103(3):192-200. PubMed ID: 8122835
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of voicing and syntactic complexity on sign expression in adductor spasmodic dysphonia.
    Erickson ML
    Am J Speech Lang Pathol; 2003 Nov; 12(4):416-24. PubMed ID: 14658993
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Botulinum toxin in the treatment of recalcitrant mutational dysphonia.
    Woodson GE; Murry T
    J Voice; 1994 Dec; 8(4):347-51. PubMed ID: 7858670
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of botulinum toxin on vocal tract steadiness in patients with spasmodic dysphonia.
    Zwirner P; Murry T; Woodson GE
    Eur Arch Otorhinolaryngol; 1997; 254(8):391-5. PubMed ID: 9332896
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Successful treatment of selected cases of abductor spasmodic dysphonia using botulinum toxin injection.
    Ludlow CL; Naunton RF; Terada S; Anderson BJ
    Otolaryngol Head Neck Surg; 1991 Jun; 104(6):849-55. PubMed ID: 1908979
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia.
    Stong BC; DelGaudio JM; Hapner ER; Johns MM
    Arch Otolaryngol Head Neck Surg; 2005 Sep; 131(9):793-5. PubMed ID: 16172357
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
    Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
    J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Laryngeal aerodynamic aspects of women with adductor spasmodic dysphonia.
    Sapienza CM; Crary MA; Gorham M
    Arch Otolaryngol Head Neck Surg; 1996 Apr; 122(4):385-8. PubMed ID: 8600922
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combined modality treatment of adductor spasmodic dysphonia.
    Silverman EP; Garvan C; Shrivastav R; Sapienza CM
    J Voice; 2012 Jan; 26(1):77-86. PubMed ID: 21292439
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Does botulinum toxin alter laryngeal secretions and mucociliary transport?
    Fisher KV; Giddens CL; Gray SD
    J Voice; 1998 Sep; 12(3):389-98. PubMed ID: 9763190
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
    Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
    J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Central auditory evaluation of patients with spasmodic dysphonia.
    Middleton ML; Wilson KM; Keith RW
    Ear Nose Throat J; 1997 Oct; 76(10):710-5. PubMed ID: 9345814
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
    Blitzer A; Brin MF; Stewart CF
    Laryngoscope; 1998 Oct; 108(10):1435-41. PubMed ID: 9778279
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment of the interarytenoid muscle with botulinum toxin for laryngeal dystonia.
    Hillel AD; Maronian NC; Waugh PF; Robinson L; Klotz DA
    Ann Otol Rhinol Laryngol; 2004 May; 113(5):341-8. PubMed ID: 15174759
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin.
    Brin MF; Blitzer A; Stewart C
    Adv Neurol; 1998; 78():237-52. PubMed ID: 9750921
    [No Abstract]   [Full Text] [Related]  

  • 79. A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia.
    Maloney AP; Morrison MD
    J Otolaryngol; 1994 Jun; 23(3):160-4. PubMed ID: 8064952
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Acoustic variations in adductor spasmodic dysphonia as a function of speech task.
    Sapienza CM; Walton S; Murry T
    J Speech Lang Hear Res; 1999 Feb; 42(1):127-40. PubMed ID: 10025549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.